Summary
An ever-growing number of cytokines that play a critical role as soluble mediators of immune and inflammatory responses are being described. Not surprisingly, most of them have been detected in SF or serum of patients with RA. However, given the numerous interactions within the cytokine network — e.g. agonistic and antagonistic properties and natural inhibitors — one should beware of over-simplistic views, the more so as extrapolation fromin vitro and animal models is always a challenge. From a clinical viewpoint, more work is required before measurements of cytokines in RA be used as activity indices and — more importantly-as prognostic markers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Miossec, P. Cytokine abnormalities in inflammatory arthritis. In: Baillière's Clinical Rheumatology, Ed.: Emery, P., London, Baillière Tindall, 1992, 373–392.
Houssiau, F.A., Devogelaer, J.-P., Van Damme, J., Nagant de Deuxchaisnes, C., Van Snick, J. Interleukin 6, in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988, 31, 784–788.
Stimpson, S.A., Dalldorf, F.G., Otterness, I.G., Schwab, J.H. Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan-polysaccharide. J Immunol 1988, 140, 2964–2969.
di Giovine, F.S., Duff, G.W. Interleukin 1: the first interleukin. Immunol Today 1990, 11, 13–20.
Eisenberg, S.P., Evans, R.J., Arend, W.P., Verderber, E., Brewer, M.T., Hannum, C.H., Thompson, R.C. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990, 343, 341–346.
Malyak, M., Swaney, R.E., Arend, W.P. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 1993, 36, 781–789.
Saxne, T., Palladino, M.A.Jr, Heinegard, D., Talal, N., Wollheim, F.A. Detection of tumor necrosis factor α but not tumor necrosis β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988, 31, 1041–1045.
Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., Kollias, G. Transgenic mice expressing human tumour necrosis α: a predictive genetic model of arthritis. EMBO J 1991, 10, 4025–4031.
Seckinger, P., Zhang, J.H., Hauptmann, B. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990, 87, 5188–5192.
Lotz, M., Guerne, P.-A. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 1991, 266, 2017–2020.
Ishimi, Y., Miyaura, C., Jin, C.H., Akatsu, T., Abe, E., Nakamura, Y., Yamaguchi, A., Yoshiki, S., Hirano, T., Kishimoto, T., Suda, T. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990, 145, 3297–3303.
Brandes, M.E., Allen, J.B., Ogawa, Y., Wahi, S.M. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991, 87, 1108–1113.
Dubois, C.M., Ruscetti, F.W., Palaszynski, E.W., Falk, L.A., Oppenheim, J.J., Keller, J.R. Transforming growth factor β is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med 1990, 172, 737–744.
Turner, M., Chantry, D., Katsikis, P., Berger, A., Brennan, F.M., Feldmann, M. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor β. Eur J Immunol 1991, 21, 1635–1639.
Eastgate, J.A., Symons, J.A., Wood, N.C., Grinlinton, F.M., di Giovine, F.S., Duff, G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988, ii, 706–709.
di Giovine, F.S., Symons, J.A., Wilson, G., Duff, G.W. Interleukins and arthritis. In: Autoimmune connective tissue diseases 1st ed., Eds.: Khamashta, M.A., Font, J., Hughes, G.R.V., Barcelona, Ediciones Doyma, 1993, 11–26.
Keystone, E.C., Snow, K.M., Bombardier, C., Chang, C.H., Nelson, D.L., Rubin, L.A. Elevated soluble IL-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 1988, 31, 844–849.
Barrera, P., Boerbooms, A.M.T., Janssen, E.M., Sauerwein, R.W., Gallati, H., Mulder, J., de Boo, T., Demacker, P.N.M., van de Putte, L.B.A., van der Meer, J.W.M. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993, 36, 1070–1079.
Dinarello, C.A., Thompson, R.C., Blocking IL-1: interleukin 1 receptor antagonistin vivo and in vitro. Immunol Today 1991, 12, 404–410.
Eliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, M.J., Walker, J., Bijl, H., Ghrayeb, J., Woody, J.N. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993, 36, 1681–1690.
Moore, K.W., O'Garra, A., de Waal Malafyt, R., Vieira, P., Mosmann, T.R. Interleukin-10. Ann Rev Immunol 1993, 11, 165–190.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Houssiau, F.A. Cytokines in rheumatoid arthritis. Clin Rheumatol 14 (Suppl 2), 10–13 (1995). https://doi.org/10.1007/BF02215851
Issue Date:
DOI: https://doi.org/10.1007/BF02215851